Pharma Capsules - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Capsules
News and Views

Pharmaceutical Technology


Atlas Hires Senior Technical Consultant

Atlas Material Testing Technology (Chicago, IL, http://www.atlas-mts.com/) named David Dumbleton its senior technical consultant for the newly created Atlas Consulting Group. Dumbleton will lend his expertise in environmental durability and performance to Atlas's customers and expand the North American consultingservices group.

Dumbleton's experience includes technical and business management in the polymer-materials industry. He previously worked as a director of research and development at Alcoa Flexible Packaging.

Expansions

BASF Adds THF Capacity at Ludwigshafen Site

BASF (Florham Park, NJ http://www.basf.com/) is expanding its annual capacity for the intermediate tetrahydrofuran (THF) by 30, 000 tons at its Ludwigshafen site. The expansion will raise the company's annual THF capacity to 210, 000 metric tons by the end of 2007.

THF is used in complex water-sensitive reactions frequently needed to produce active pharmaceutical ingredients. BASF supplies high-purity THF with a low residual water content of 0.01%.

Future Pak Moves to Larger Facility

Future Pak Ltd. (Wixom, MI, http://www.futurepak.com/), a contract packager, moved its solid-dose packaging operations to a new location. Three blister suites, 12 form–fill–seal lines, and soliddose bottling operations moved to a 32, 000-ft2 facility in Wixom, Michigan.

The site will provide space for the expansion of the company's blister-packaging capacity. During the past three years, Future Pak's annual packaging volume grew to 1800 batches, or about 7 billion tablets.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
8%
All of the above.
45%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here